查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586227

子宮頸癌診斷市場：按類型、最終用戶分類 - 全球預測 2025-2030

Cervical Cancer Diagnostic Market by Type (Cervical Biopsies, Colposcopy, Cystoscopy), End-User (Cancer & Radiation Therapy Centers, Hospital, Speciality Clinics & Diagnostic Centers) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年子宮頸癌診斷市場價值為201.4億美元，預計到2024年將達到221.5億美元，複合年成長率為10.03%，到2030年將達到393.5億美元。

子宮頸癌診斷市場包括旨在檢測和診斷子宮頸癌的各種工具和技術。該系列包括子宮頸抹片、HPV 檢測、切片檢查和先進的成像工具，為早期診斷提供了多方面的方法，這對於實現有效的治療結果至關重要。這些診斷的需求源於透過早期檢測降低子宮頸癌死亡率的需要以及 HPV 感染的全球盛行率。應用主要集中在進行常規醫療檢查的婦女診所、醫院和診斷實驗室，重點是旨在加強患者護理和管理的醫療服務的最終用途。市場成長受到人們對子宮頸癌認知不斷提高、政府推動子宮頸癌篩檢計畫的舉措以及診斷工具技術進步等因素的顯著影響。潛在的機會包括擴大新興市場的篩檢計劃以及整合人工智慧和機器學習以提高診斷準確性和效率。創新者可以透過開發新型診斷分析和可攜式測試設備來獲得資金，以滿足資源匱乏環境和遠端醫療應用的需求。儘管潛力巨大，但該市場仍面臨挑戰，例如先進診斷程序的高成本、農村地區獲得醫療保健的機會有限以及影響產品核可時間表的監管障礙。透過政策建議和對負擔得起的診斷技術的投資來解決這些限制將推動市場成長。研究和開發工作應著重於個人化醫療方法和非侵入性診斷的開發，以提高患者的依從性。市場充滿活力且競爭激烈，駕馭複雜性並抓住機會需要持續創新和策略夥伴關係。

主要市場統計
基準年[2023] 201.4億美元
預測年份 [2024] 221.5億美元
預測年份 [2030] 393.5億美元
複合年成長率（%） 10.03%

市場動態：快速發展的子宮頸癌診斷市場的關鍵市場洞察

供需的動態交互作用正在改變子宮頸癌診斷市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 子宮頸癌患者增加
    • 非侵入性手術越來越受歡迎和傾向
    • 政府擴大醫療基礎設施的舉措
  • 市場限制因素
    • 與診斷程序相關的高成本
  • 市場機會
    • 癌症診斷設備的發展和技術進步
    • 管道診斷工具繼續核准監管機構批准
  • 市場挑戰
    • 嚴格且耗時的法規環境

波特五力：駕馭子宮頸癌診斷市場的策略工具

波特的「五力」框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對子宮頸癌診斷市場的影響

外部宏觀環境因素在塑造子宮頸癌診斷市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解子宮頸癌診斷市場的競爭狀況

子宮頸癌診斷市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣子宮頸癌診斷市場供應商的績效評估

FPNV 定位矩陣是評估子宮頸癌診斷市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了子宮頸癌診斷市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對子宮頸癌診斷市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 子宮頸癌發生率增加
      • 非侵入性手術的日益普及和趨勢
      • 政府努力擴大醫療基礎設施
    • 抑制因素
      • 與診斷程序相關的高成本
    • 機會
      • 癌症診斷設備的發展與技術進步
      • 管道診斷工具繼續核准監管機構批准
    • 任務
      • 耗時且嚴格的法規環境
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章子宮頸癌診斷市場：依類型

  • 子宮頸切片檢查
  • 陰道鏡檢查
  • 膀胱鏡檢查
  • HPV檢測
  • 子宮頸抹片檢查

第7章子宮頸癌診斷市場：依最終用戶分類

  • 癌症與放射治療中心
  • 醫院
  • 專科診所和診斷中心

第8章北美和南美子宮頸癌診斷市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區子宮頸癌診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲子宮頸癌診斷市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Advaxis Inc.
  • Arbor Vita Corporation
  • Beckman Coulter Inc. by Danaher Corporation
  • Becton, Dickinson and Company
  • Bio Farma
  • Bristol-Myers Squibb Company
  • Cardinal Health, Inc.
  • CooperSurgical, Inc.
  • Dr Lal PathLabs Pvt. Ltd.
  • DYSIS Medical Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hologic, Inc.
  • Merck & Co. Inc.
  • MobileODT
  • oncgnostics GmbH
  • Qiagen NV
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Zilico Ltd.
Product Code: MRR-4756B70362E8

The Cervical Cancer Diagnostic Market was valued at USD 20.14 billion in 2023, expected to reach USD 22.15 billion in 2024, and is projected to grow at a CAGR of 10.03%, to USD 39.35 billion by 2030.

The cervical cancer diagnostic market encompasses a range of tools and techniques aimed at detecting and diagnosing cervical cancer. This scope includes Pap smears, HPV testing, biopsies, and advanced imaging tools, which together provide a multi-faceted approach to early diagnosis, critical for effective treatment outcomes. The necessity for these diagnostics stems from the need to reduce cervical cancer mortality rates through early detection and the growing prevalence of HPV infections globally. Applications are primarily focused on women's health clinics, hospitals, and diagnostic laboratories where routine screenings are conducted, emphasizing the end-use scope in healthcare services that aim to enhance patient care and management. Market growth is significantly influenced by factors such as increasing awareness of cervical cancer, government initiatives promoting cervical screening programs, and technological advancements in diagnostic tools. Potential opportunities include the expansion of screening programs in emerging markets and the integration of AI and machine learning to improve diagnostic accuracy and efficiency. Innovators can capitalize by developing novel diagnostic assays and portable testing devices to meet the needs of low-resource settings and telemedicine applications. Despite its potential, the market faces challenges such as high costs of advanced diagnostic procedures, limited access to healthcare in rural areas, and regulatory hurdles affecting product approval timelines. Addressing these limitations through policy advocacy and investment in affordable diagnostic technologies can foster market growth. R&D efforts should focus on personalized medicine approaches and developing non-invasive diagnostic methods to enhance patient compliance. The market is dynamic and competitive, requiring continuous innovation and strategic partnerships to navigate its complexities and seize opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 20.14 billion
Estimated Year [2024] USD 22.15 billion
Forecast Year [2030] USD 39.35 billion
CAGR (%) 10.03%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cervical Cancer Diagnostic Market

The Cervical Cancer Diagnostic Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cervical cancer cases
    • Rising popularity and inclination towards non-invasive procedures
    • Government initiatives to expand healthcare infrastructure
  • Market Restraints
    • High cost associated with diagnostic procedures
  • Market Opportunities
    • Development and technological advancements in cancer diagnostic devices
    • Ongoing approvals from regulatory agencies of pipeline diagnostic tools
  • Market Challenges
    • Time-consuming and stringent regulatory environment

Porter's Five Forces: A Strategic Tool for Navigating the Cervical Cancer Diagnostic Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cervical Cancer Diagnostic Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cervical Cancer Diagnostic Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cervical Cancer Diagnostic Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cervical Cancer Diagnostic Market

A detailed market share analysis in the Cervical Cancer Diagnostic Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cervical Cancer Diagnostic Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cervical Cancer Diagnostic Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cervical Cancer Diagnostic Market

A strategic analysis of the Cervical Cancer Diagnostic Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cervical Cancer Diagnostic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Advaxis Inc., Arbor Vita Corporation, Beckman Coulter Inc. by Danaher Corporation, Becton, Dickinson and Company, Bio Farma, Bristol-Myers Squibb Company, Cardinal Health, Inc., CooperSurgical, Inc., Dr Lal PathLabs Pvt. Ltd., DYSIS Medical Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Hologic, Inc., Merck & Co. Inc., MobileODT, oncgnostics GmbH, Qiagen NV, Quest Diagnostics Incorporated, Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Zilico Ltd..

Market Segmentation & Coverage

This research report categorizes the Cervical Cancer Diagnostic Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Cervical Biopsies, Colposcopy, Cystoscopy, HPV Testing, and Pap Smear Test.
  • Based on End-User, market is studied across Cancer & Radiation Therapy Centers, Hospital, and Speciality Clinics & Diagnostic Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cervical cancer cases
      • 5.1.1.2. Rising popularity and inclination towards non-invasive procedures
      • 5.1.1.3. Government initiatives to expand healthcare infrastructure
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with diagnostic procedures
    • 5.1.3. Opportunities
      • 5.1.3.1. Development and technological advancements in cancer diagnostic devices
      • 5.1.3.2. Ongoing approvals from regulatory agencies of pipeline diagnostic tools
    • 5.1.4. Challenges
      • 5.1.4.1. Time-consuming and stringent regulatory environment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cervical Cancer Diagnostic Market, by Type

  • 6.1. Introduction
  • 6.2. Cervical Biopsies
  • 6.3. Colposcopy
  • 6.4. Cystoscopy
  • 6.5. HPV Testing
  • 6.6. Pap Smear Test

7. Cervical Cancer Diagnostic Market, by End-User

  • 7.1. Introduction
  • 7.2. Cancer & Radiation Therapy Centers
  • 7.3. Hospital
  • 7.4. Speciality Clinics & Diagnostic Centers

8. Americas Cervical Cancer Diagnostic Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cervical Cancer Diagnostic Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cervical Cancer Diagnostic Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Advaxis Inc.
  • 3. Arbor Vita Corporation
  • 4. Beckman Coulter Inc. by Danaher Corporation
  • 5. Becton, Dickinson and Company
  • 6. Bio Farma
  • 7. Bristol-Myers Squibb Company
  • 8. Cardinal Health, Inc.
  • 9. CooperSurgical, Inc.
  • 10. Dr Lal PathLabs Pvt. Ltd.
  • 11. DYSIS Medical Inc.
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. GlaxoSmithKline PLC
  • 14. Hologic, Inc.
  • 15. Merck & Co. Inc.
  • 16. MobileODT
  • 17. oncgnostics GmbH
  • 18. Qiagen NV
  • 19. Quest Diagnostics Incorporated
  • 20. Siemens Healthineers AG
  • 21. Thermo Fisher Scientific Inc.
  • 22. Zilico Ltd.

LIST OF FIGURES

  • FIGURE 1. CERVICAL CANCER DIAGNOSTIC MARKET RESEARCH PROCESS
  • FIGURE 2. CERVICAL CANCER DIAGNOSTIC MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CERVICAL CANCER DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CERVICAL CANCER DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CERVICAL CANCER DIAGNOSTIC MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CERVICAL CANCER DIAGNOSTIC MARKET DYNAMICS
  • TABLE 7. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY CERVICAL BIOPSIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COLPOSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY CYSTOSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY HPV TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY PAP SMEAR TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY CANCER & RADIATION THERAPY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY SPECIALITY CLINICS & DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. CERVICAL CANCER DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 104. CERVICAL CANCER DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2023